Hims & Hers Stock Soars 33%—Thanks to Novo Nordisk’s Wegovy Lifeline

Another day, another pharma stock propped up by Big Pharma’s favorite trick: throwing money at the problem.

Hims & Hers—the telehealth darling that turned ‘erectile dysfunction’ into a marketable brand—just clawed back a third of its value after inking a deal with Novo Nordisk for its weight-loss drug Wegovy. Because nothing says ‘growth strategy’ like hitching your wagon to the Ozempic craze.

Wall Street’s buying it (literally). But let’s see how long the sugar high lasts.

Early 2025 Rally Fades, but Technical Support Holds

At the beginning of the year, Hims & Hers Health stock experienced a powerful rally, surging past $73 in early February amid growing investor enthusiasm for digital health solutions. However, as broader market sentiment deteriorated, particularly across growth-oriented stocks, HIMS began a steady descent. By the end of April, shares had dropped to $28.48, brushing against key technical support at the 200-day simple moving average, which hovered around $25.

That level held firm, and late last week, the stock began reversing higher — a move that gained serious traction today.

Massive Bullish Gap After Wegovy Partnership

On Tuesday, HIMS shares exploded over 26% higher at the open, surging to $37 in response to a major business development, while climbing 33% in several days. The company announced a new collaboration with Danish pharmaceutical heavyweight Novo Nordisk (NVO), aimed at offering the blockbuster weight-loss drug Wegovy to Hims & Hers’ customers via its telehealth platform.

HIMS Stock Chart Daily – Pushing Above MAs

Starting this week, users will be able to purchase a bundled package that includes a full range of Wegovy doses along with a Hims & Hers membership, priced from $599. The partnership significantly expands the company’s weight-loss treatment offerings, addressing a growing demand in the digital health market.

Earlier this month, Hims & Hers had also revealed plans to make branded tirzepatide — the active ingredient in Eli Lilly’s Zepbound and Mounjaro — available through its platform. Eli Lilly was quick to clarify that it has no direct relationship with Hims & Hers, emphasizing that licensed providers may prescribe its medications independently.

Stock Nearly Triples Over the Year, Q1 Earnings Ahead

Thanks to today’s surge, HIMS stock has now nearly tripled over the past 12 months, reflecting increasing investor interest in telehealth and prescription wellness solutions. The timing of this announcement is particularly strategic, as the company is scheduled to report its first-quarter earnings next Monday.

With growing traction in the weight-loss drug market and consumer demand surging for accessible health options, investors will be closely watching whether Hims & Hers can translate this momentum into revenue growth and long-term profitability.